| 摘要 |
The invention is directed to small molecule inverse agonists of the liver X receptor, LXR. These compounds have potential use in the treatment of the following disorders: non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, obesity, insulin resistance, and metabolic syndrome. The invention is directed, in various embodiments, to small molecule inverse agonists of the liver X receptor, LXR. Administration of an effective amount of a compound of the invention, such as compound of formula (I), can be used to suppress hepatic lipogenesis, inflammation, or hepatic lipid accumulation in a mammal. |
